Regenerative Medical Technology (RMTG) Net Cash Flow (2018 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly Net Cash Flow of $104730.0 for Q1 2026, up 83.39% year-over-year from $57109.0 in Q1 2025, and up 145.74% quarter-over-quarter from -$228976.0 in Q4 2025.
Regenerative Medical Technology (RMTG) Net Cash Flow (2018 - 2026) Analysis & Trends
Regenerative Medical Technology's Net Cash Flow history runs 9 years deep, the most recent figure standing at $104730.0 for Q1 2026.
- In Q1 2026, Net Cash Flow rose 83.39% year-over-year to $104730.0; the TTM figure through Mar 2026 stood at -$1.2 million (down 278.83% YoY), while the FY2025 annual figure was -$209102.0, down 132.91% from the prior year.
- Net Cash Flow for Q1 2026 stood at $104730.0, up from -$228976.0 in the prior quarter.
- The five-year high for Net Cash Flow was $329393.0 in Q4 2024, with the low at -$613401.0 in Q4 2023.
- The 5-year median for Net Cash Flow is -$124451.0 (2022), against an average of -$163403.3.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow soared 670.17% in 2024, then sank 1684.73% in 2025.
- Regenerative Medical Technology's Net Cash Flow stood at -$124451.0 in 2022, then sank by 392.89% to -$613401.0 in 2023, then soared by 153.7% to $329393.0 in 2024, then slumped by 169.51% to -$228976.0 in 2025, then jumped by 145.74% to $104730.0 in 2026.
- Business Quant data shows RMTG's Net Cash Flow at $104730.0 in Q1 2026, -$228976.0 in Q4 2025, and -$428560.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Regenerative Medical Technology | 1.58 Mn | 515,228.12 | 1.77 Mn | 104,730.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 104,730.00 |
| Mar 31, 2026 | 104,730.00 |
| Dec 31, 2025 | -228,976.00 |
| Dec 31, 2025 | -228,976.00 |
| Sep 30, 2025 | -428,560.00 |
| Sep 30, 2025 | -428,560.00 |
| Jun 30, 2025 | -598,093.00 |
| Jun 30, 2025 | -598,093.00 |
| Mar 31, 2025 | 57,109.00 |
| Mar 31, 2025 | 57,109.00 |
| Dec 31, 2024 | 329,393.00 |
| Dec 31, 2024 | 329,393.00 |
| Sep 30, 2024 | 219,334.00 |
| Sep 30, 2024 | 219,334.00 |
| Jun 30, 2024 | 37,741.00 |
| Jun 30, 2024 | 37,741.00 |
| Mar 31, 2024 | 48,812.00 |
| Mar 31, 2024 | 48,812.00 |
| Dec 31, 2023 | -613,401.00 |
| Dec 31, 2023 | -613,401.00 |